PRL modulates cell cycle regulators in mammary tumor epithelial cells

Molecular Endocrinology

Volumn 16, Issue 1, 2002, Pages 45-57

  Schroeder, Matthew D ^a   Symowicz, Jaime ^a   Schuler, Linda A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTISENSE OLIGONUCLEOTIDE; CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN E; EPIDERMAL GROWTH FACTOR; PROLACTIN; RETINOBLASTOMA PROTEIN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; BREAST TUMOR; CELL CYCLE; CONTROLLED STUDY; EPITHELIUM CELL; HORMONAL REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0036140024     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.16.1.0762     Document Type: Article

References (65)

1. Defective mammopoiesis, but normal hematopolesis, in mice with a targeted disruption of the prolactin gene
2. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse
3. Prolactin controls mammary gland development via direct and indirect mechanisms
4. Prolactin and murine mammary tumorigenesis: A review
5. Prolactin and the induction of mammary tumors in mice
6. Expression of prolactin and its receptor in human breast carcinoma
7. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors vs. normal breast tissues
8. Prolactin in human breast cancer development
9. Should prolactin be reconsidered as a therapeutic target in human breast cancer
10. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women
11. The role of prolactin and growth hormone in breast cancer
12. Extrapituitary prolactin: Distribution, regulation, functions, and clinical aspects
13. Prolactin as an autocrine/paracrine factor in breast cancer
14. Expression of the prolactin gene in normal and neoplastic human breast tissues and human breast cell lines: Promoter usage and alternative mRNA splicing
15. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines
16. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation
17. CDK inhibitors: Positive and negative regulators of G1-phase progression
18. 1 cyclin dependent kinases in the mammalian cell cycle
19. Cell-cycle inhibitors: Three families united by a common cause
20. Targeting of an inducible toxic phenotype in animal cells
21. Antiviral activity and mechanism of action of ganciclovir
22. Estrogen-induced activation of cdk4 and cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-cdk2
23. The antiestrogen ICI 182,780 inhibits proliferation of human breast cancer cells by interfering with multiple, sequential estrogen-regulated processes required for cell cycle completion
24. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2
25. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation
26. Defining the substrate specificity of cdk4 kinase-cyclin D1 complex
27. Prolactin (PRL) and its receptor: Actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice
28. Prolactin-induced cell proliferation in PC12 cells depends on JNK but not ERK activation
29. Prolactin (PRL)-PRL receptor system increases cell proliferation involving JNK (c-Jun amino terminal kinase) and AP-1 activation: Inhibition by glucocorticoids
30. Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer
31. Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines
32. Cyclin E, a redundant cyclin in breast cancer
33. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis
34. Mammary gland oncogenes as indicators of pathways important in mammary gland development
35. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle
36. A specific role for cyclin D1 in mammary gland development
37. Cyclin D1 expression in invasive breast cancer: Correlations and prognostic value
38. Cyclin D1 in mammary carcinoma
39. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
40. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation
41. Expression of prolactin and prolactin receptor in human breast carcinoma: Evidence for an autocrine/paracrine loop
42. Functional characterization of the intermediate isoform of the human prolactin receptor
43. Prolactin signaling in mammary gland development
44. Redundant cyclin overexpression and gene amplification in breast cancer cells
45. Expression of the G2-M checkpoint regulators cyclin B1 and P34CDC2 in breast cancer: A correlation with cellular kinetics
46. Regulating the onset of mitosis
47. Mechanisms and regulation of ubiquitin-mediated cyclin degradation
48. Four-dimensional control of the cell cycle
49. Combinatorial control of cyclin B1 nuclear trafficking through phosphorylation at multiple sites
50. Identification of CIP-1-associated regulator of cyclin B (CARB), a novel p21-binding protein acting in the G2 phase of the cell cycle
51. Transcriptional regulation of the p21(WAF1/CIP1) gene
52. WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: Role of activated STAT3 signaling
53. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components
54. Convergence of progesterone with growth factor and cytokine signaling in breast cancer: Progesterone receptors regulate signal transducers and activators of transcription expression and activity
55. The role of p21 in interferon gamma-mediated growth inhibition of human breast cancer cells
56. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) mediated by Stat 1
57. Prolactin recruits STAT1, STAT3 and STAT5 independent of conserved receptor tyrosines TYR402, TYR479, TYR515 and TYR580
58. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer
59. Crosstalk between the insulin-like growth factors and estrogens in breast cancer
60. Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals
61. A pure enstrogen antagonist inhibits cyclin E-cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence
62. Interactions among JANUS kinases and the prolactin (PRL) receptor in the regulation of a PRL response element
63. Transcriptional regulation of interleukin-1β gene by interleukin- 1β itself is mediated in part by Oct-1 in thymic stromal cells
64. Prolactin-stimulated growth of cell cultures established from malignant Nb rat lymphomas
65. Dysregulation of signal transducers and activators of transcription 1, 3, and 5 and prolactin receptors by overexpression of mammary TGFα